Viatris Pacira Acquisition Closes: $1.65B Buys Exparel and a Non-Opioid Pain Franchise
Viatris has closed its $1.65 billion, $36.50-a-share purchase of Pacira BioSciences, adding non-opioid pain drugs Exparel and Zilretta. Deal numbers, strategy and risks explained.
